ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
AstraZeneca and Lilly to develop second potentially disease-modifying treatment for Alzheimer's dise
January 16, 2017AstraZeneca and Eli Lilly and Company have announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in Phase I trials as a potential disease-modifying treatment for Alzheimer's disease (A
Pharma Sources Insight January 2025
